Aldeyra TherapeuticsALDX
Market Cap: $364M
About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Employees: 10
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
395% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $219K
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
3% more funds holding
Funds holding: 100 [Q1] → 103 (+3) [Q2]
6% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% less capital invested
Capital invested by funds: $117M [Q1] → $117M (-$26.3K) [Q2]
1.23% less ownership
Funds ownership: 60.71% [Q1] → 59.47% (-1.23%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Matthew Caufield 29% 1-year accuracy 12 / 41 met price target | 63%upside $10 | Buy Reiterated | 9 Aug 2024 |
HC Wainwright & Co. Matthew Caufield 29% 1-year accuracy 12 / 41 met price target | 63%upside $10 | Buy Reiterated | 2 Aug 2024 |
Financial journalist opinion
Based on 4 articles about ALDX published over the past 30 days